P-Cresol

P-Cresol

SCHEMBL2286028

Cc1ccc(O)cc1.F

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Cresol SCHEMBL375 0.96 — —
P-Cresol SCHEMBL9726112 0.96 ACHE (1.00) —
P-Cresol SCHEMBL11263098 0.96 ACHE (1.00) —
P-Xylene SCHEMBL28199191 0.96 ACHE (1.00) —
P-Cresol SCHEMBL960690 0.96 ACHE (1.00) —
P-Cresol SCHEMBL9490270 0.93 — —
P-Cresol SCHEMBL8888377 0.93 ACHE (0.93) —
P-Cresol SCHEMBL9490278 0.93 — —
P-Cresol SCHEMBL8508863 0.93 ACHE (0.93) —
P-Cresol SCHEMBL4459881 0.93 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110184147-A1 ENZYME SUBSTRATE FOR LABELING OF PROTEIN KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2011-07-28 — — US disclosed
EP-0600884-B1 PROTECTIVE FOUR AMINO ACID EPITOPE AGAINST PLASMODIUM VIVAX MALARIA US GOV SEC NAVY (US) 2003-03-05 — — EP disclosed
US-6399062-B1 INJECTABLE SOLUTION OF NAVY VIVAX SPOROZOITE 3 (HB10615) FOR TEMPORARY IMMUNIZATION; UNIQUE SPECIFICITY THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY 2002-06-04 — — US disclosed
US-5599543-A PREVENTING MALARIA THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1997-02-04 — — US disclosed
US-5095093-A Protective four amino acid epitope against Plasmodium vivax malaria THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1992-03-10 — — US disclosed
Send feedback